| Completed | Evaluate the Effect of Vimseltinib on Organic Cation Transporter 2 (OCT2) Healthy Participants | Phase 1 | 2025-11-20 |
| Completed | Evaluate the Effect of Vimseltinib on the Pharmacokinetics of a BCRP and OATP1B1 Substrate Healthy Participants | Phase 1 | 2025-10-31 |
| Recruiting | Tenosynovial Giant Cell Tumor (TGCT) Real-World Participant Experience With Vimseltinib Tenosynovial Giant Cell Tumor | — | 2025-09-03 |
| Recruiting | Study of DCC-2812 in Participants With Advanced Genitourinary Cancers Renal Cell Carcinoma, Urothelial Carcinoma, Castration-resistant Prostate Cancer | Phase 1 | 2025-08-27 |
| Recruiting | A Master Protocol to Evaluate DCC-3009 in Gastrointestinal Stromal Tumor (GIST) Gastrointestinal Stromal Tumor (GIST) | Phase 1 / Phase 2 | 2024-12-10 |
| Recruiting | A Study to Evaluate Vimseltinib in Adults With Active Chronic Graft-Versus-Host Disease (cGVHD) Chronic Graft-Versus-Host Disease (cGVHD) | Phase 2 | 2024-11-21 |
| Terminated | Study of DCC-3084 in Participants With Advanced Malignancies Driven by the Mitogen-Activated Protein Kinase (M Advanced Solid Tumor, RAF Mutation, RAS Mutation | Phase 1 | 2024-05-14 |
| Active Not Recruiting | A Study of Ripretinib vs Sunitinib in Patients With Advanced GIST With Specific KIT Exon Mutations Who Were Pr GIST | Phase 3 | 2023-12-13 |
| Recruiting | A Study of Inlexisertib (DCC-3116) in Combination With Anticancer Therapies in Participants With Advanced Mali GIST | Phase 1 / Phase 2 | 2023-09-28 |
| Withdrawn | Ripretinib in Combination With Binimetinib in Patients With Gastrointestinal Stromal Tumor (GIST) Gastrointestinal Stromal Tumors | Phase 1 / Phase 2 | 2021-11-01 |
| Active Not Recruiting | Study of Vimseltinib for Tenosynovial Giant Cell Tumor Tenosynovial Giant Cell Tumor, Pigmented Villonodular Synovitis, Giant Cell Tumor of Tendon Sheath | Phase 3 | 2021-10-14 |
| Completed | A Drug-Drug Interaction Study to Evaluate the Effect of Ripretinib on the Pharmacokinetics of a CYP2C8 Probe S GIST - Gastrointestinal Stromal Tumor | Phase 1 | 2021-09-22 |
| Terminated | Study of Inlexisertib (DCC-3116) in Participants With RAS/MAPK Pathway Mutant Solid Tumors Non-Small Cell Lung Cancer, Advanced Solid Tumor, Metastatic Solid Tumor | Phase 1 | 2021-06-15 |
| Active Not Recruiting | A Study of Ripretinib vs Sunitinib in Advanced GIST Patients After Treatment With Imatinib Gastrointestinal Stromal Tumors | Phase 3 | 2019-02-08 |
| Terminated | A Study of Rebastinib (DCC-2036) in Combination With Carboplatin in Patients With Advanced or Metastatic Solid Locally Advanced or Metastatic Solid Tumor | Phase 1 / Phase 2 | 2019-01-02 |
| Terminated | A Phase 1b/2 Study of Rebastinib (DCC-2036) in Combination With Paclitaxel in Patients With Advanced or Metast Locally Advanced or Metastatic Solid Tumor | Phase 1 / Phase 2 | 2018-10-25 |
| Completed | Phase 3 Study of DCC-2618 vs Placebo in Advanced GIST Patients Who Have Been Treated With Prior Anticancer The Gastrointestinal Stromal Tumors | Phase 3 | 2018-02-27 |
| Active Not Recruiting | Study of Vimseltinib (DCC-3014) in Patients With Advanced Tumors and Tenosynovial Giant Cell Tumor Advanced Malignant Neoplasm, Pigmented Villonodular Synovitis, Giant Cell Tumor of Tendon Sheath | Phase 1 / Phase 2 | 2017-02-16 |
| Completed | A Safety, Tolerability and PK Study of DCC-2618 in Patients With Advanced Malignancies Gastrointestinal Stromal Tumors, Advanced Systemic Mastocytosis, Advanced Cancers | Phase 1 | 2015-11-01 |
| Terminated | A Study of DCC-2701 in Participants With Advanced Solid Tumors Locally Advanced Tumors, Metastatic Solid Tumors, Cancers With MET Genomic Alterations | Phase 1 | 2014-06-01 |
| Completed | Study Safety and Preliminary Efficacy of DCC-2036 in Patients With Leukemias (Ph+ CML With T315I Mutation) Chronic Myeloid Leukemia | Phase 1 | 2009-03-01 |
| Approved For Marketing | Expanded Access Program of Ripretinib (DCC-2618) for the Treatment of Patients With Advanced GIST GIST - Gastrointestinal Stromal Tumor | — | — |